Advertisement

European Journal of Pediatrics

, Volume 171, Issue 12, pp 1767–1773 | Cite as

Prevalence and management of gastroesophageal reflux disease in children and adolescents: a nationwide cross-sectional observational study

  • Léonie Martigne
  • Pierre-Henri Delaage
  • Florence Thomas-Delecourt
  • Geneviève Bonnelye
  • Philippe Barthélémy
  • Frédéric GottrandEmail author
Original Article

Abstract

This cross-sectional observational study aimed to determine the nationwide prevalence of gastroesophageal reflux disease (GORD) in French children and adolescents. Four hundred four general practitioners and 180 paediatricians compiled a register of all children and adolescents (n = 10,394, aged 0 to 17 years, mean 3.8 ± 5.6 years) who presented over two 3-day periods. For all children who, in the physician's opinion, showed symptoms of gastroesophageal reflux (GOR), a 24-item questionnaire covering the history and management of GOR was completed. Children with symptoms that impaired their daily lives were defined as having GORD, the remainder as having physiological GOR. Of the patients, 15.1 % showed GOR symptoms. Extrapolation to the overall French population yielded a prevalence of 10.3 % for GOR and 6.2 % for GORD. There was a significantly (p < 0.05) greater use of volume reduction or milk thickeners and dorsal positioning among infants with GORD versus physiological GOR. Significantly (p < 0.05) more of the infants and children with GORD received pharmacological therapy. The use of proton pump inhibitors increased with age but was significantly (p < 0.05) higher among those with GORD. Conclusions: Ten percent of French children and adolescents show GOR symptoms and 6 % have GORD. Clinical presentation and treatment vary in different age groups, but those with GORD are more likely to require pharmacological treatment.

Keywords

Gastroesophageal reflux disease Child Epidemiology 

Notes

Acknowledgments

The authors would like to thank Dr Ann McIlhinney, who was funded by AstraZeneca France to assist in the preparation of this manuscript.

Conflict of interest

Pierre-Henri Delaage (PHD), Florence Thomas (FT), Philippe Barthelemy (PB) are employees of 300 AstraZeneca.

Sources of funding and role of sponsor

The study was funded by AstraZeneca France.

References

  1. 1.
    Campanozzi A, Boccia G, Pensabene L, Panetta F, Marseglia A, Strisciuglio P et al (2009) Prevalence and natural history of gastroesophageal reflux: pediatric prospective survey. Pediatrics 123:779–83PubMedCrossRefGoogle Scholar
  2. 2.
    Costa AJ, Silva GA, Gouveia PA, Pereira Filho EM (2004) Prevalence of pathologic gastroesophageal reflux in regurgitant infants. J Pediatr (Rio J) 80:291–295Google Scholar
  3. 3.
    Gold BD (2004) Gastroesophageal reflux disease: could intervention in childhood reduce the risk of later complications? Am J Med 117(Suppl 5A):23S–29SPubMedGoogle Scholar
  4. 4.
    Gottrand F (2006) Gastroesophageal reflux in childhood. Arch Pediatr 13:1076–1079PubMedCrossRefGoogle Scholar
  5. 5.
    Gupta SK, Hassall E, Chiu Y-L, Amer F, Heyman MB (2006) Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. Dig Dis Sci 51:858–63PubMedCrossRefGoogle Scholar
  6. 6.
    Kim J, Keininger DL, Becker S, Crawley JA (2005) Simultaneous development of the Pediatric GERD Caregiver Impact Questionnaire (PGCIQ) in American English and American Spanish. Health Qual Life Outcomes 3:5PubMedCrossRefGoogle Scholar
  7. 7.
    Martin AJ, Pratt N, Kennedy JD, Ryan P, Ruffin RE, Miles H et al (2002) Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 109:1061–7PubMedCrossRefGoogle Scholar
  8. 8.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK (1997) Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 151:569–72PubMedCrossRefGoogle Scholar
  9. 9.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK (1998) One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group. Pediatrics 102:E67PubMedCrossRefGoogle Scholar
  10. 10.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK (2000) Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 154:150–4PubMedGoogle Scholar
  11. 11.
    Ruigómez A, Wallander MA, Lundborg P, Johansson S, Rodriguez LA (2010) Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 45:139–46PubMedCrossRefGoogle Scholar
  12. 12.
    Sherman PM, Hassall E, Fagundes-Neto U, Gold BJ, Kato S, Koletzko S et al (2009) A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 104:1278–95PubMedCrossRefGoogle Scholar
  13. 13.
    Vakil N, van Zanten S, Kahrilas P, Dent J, Jones R, Global Consensus Group (2006) The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–20PubMedCrossRefGoogle Scholar
  14. 14.
    Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L et al (2009) Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 49:498–547PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Léonie Martigne
    • 1
  • Pierre-Henri Delaage
    • 2
  • Florence Thomas-Delecourt
    • 2
  • Geneviève Bonnelye
    • 3
  • Philippe Barthélémy
    • 2
  • Frédéric Gottrand
    • 1
    Email author
  1. 1.Unité Inserm U995, Service de Gastroentérologie, Hépatologie et Nutrition Pédiatrique, Pôle Enfant, Hôpital Jeanne de FlandreCHRU de LilleLille CedexFrance
  2. 2.AstraZenecaRueil MalmaisonFrance
  3. 3.TNS HealthcareMontrougeFrance

Personalised recommendations